CLD-401: A Systemic Gene Medicine for In Situ IL-15 Superagonist Delivery: Driving NK and γδ T Cell-Mediated Tumor Killing

Calidi Biotherapeutics Inc. published this content on July 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 27, 2026 at 21:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]